by R.A.Jones, M.D. © 2015

Beech – Fagus Sylvatica (buds)

There are many therapeutic phytochemicals, some naturally occurring, while others must be combinatorially synthesized, or produced by other than an isolated approach. To qualify as a therapeutic agent with biological activity, typically there must be a measureable and predictable, often (although not always), physiological response after either the ingestion, or the injection of therapeutic phytochemicals. While not all therapeutic phytochemicals cause identical or even similar responses, in general they do, especially when taken in similar amounts or dosages, and when they are taken under similar conditions or delivered by a similar route of administration.

A few basic ideas like these are always important to keep in mind, whenever the response to therapeutic phytochemicals undergo critical scientific evaluation or scrutiny, such as during a clinical trial, or in research which may evaluate a primary or secondary phytochemical metabolite.

Such ideas are also important when the outcome or response to a single therapeutic phytochemical is anticipated, within a clinical setting, in response to an illness, or after an inadvertent or accidental exposure to a therapeutic phytochemical, especially when there may be high doses or questions regarding toxicity. 

Herein lies one of the first and most important distinctions which will be discussed during this series of newsletters, having to do with embryonic PSC® derivatives, because when it comes to the use of these remarkable, naturally occurring extracts, and the phytochemicals from nature’s pharmacy, it is quite rare, if not nearly impossible, for any toxicity to develop from their use, provided, of course, that they are used by a qualified and skilled practitioner, with the clinical expertise to use embryonic plant extracts.

Unlike the study of pharmacologically isolated synthetic or natural chemicals, the fundamental pharmacological basis for the use of embryonic plant extract phytochemistry is far more complex. That’s because within these embryonic plant extracts, specific combinations of naturally occurring therapeutic phytochemicals (constituents) are found, and it is these combinations of phytochemicals, rather than a single chemical, which are responsible for the therapeutic biological activities.

Many years of meticulous research, observation and studies have now led to a way to use the various known, naturally occurring combinations of therapeutic phytochemicals, which are found in different quantitative and qualitative amounts, within these embryonic plant extracts. 

After reviewing some of the basic facts about the embryonic plant extracts, their basic anatomical and therapeutic constituents, and a few other basic features pertaining to them, these newsletters will continue through an alphabetical (A-Z) parade of each of the embryonic plants.

These are the buds, young shoots, germinating seeds, internal epithelium barks, rootlets and sap of trees and shrubs from which the embryonic plant extract phytochemicals are extracted.

The newsletters will explain how and why specific embryonic plant extracts may be most useful, either individually, or in combinatorial synergy, toward the relief, improvement, or total resolution of a variety of clinical conditions and diseases. 

A special notice will also be given to those conditions for which therapy would otherwise be unavailable without the use of embryonic plant stem extracts, and to where further research for the use of embryonic plant extracts by an injectable (parenteral) route would be indicated or recommended in clinical and research investigations.

Dominique Richard is the foremost authority on the subject of embryonic phytopharmacology.

R.A.Jones, M.D.
Director of Research and Education, PSC
Internal Medicine and Emergency Medicine
Multidisciplinary Medical Mathematical Director of Research (
Editor-in-Chief (
The American Journal of Medical Mathematics
New York, New York